These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33455068)

  • 1. Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay.
    Zipkin R; Schaefer A; Chamberlin M; Onega T; O'Malley AJ; Moen EL
    Cancer Med; 2021 Feb; 10(4):1253-1263. PubMed ID: 33455068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer.
    Rotter J; Wilson L; Greiner MA; Pollack CE; Dinan M
    Breast Cancer Res Treat; 2019 Jul; 176(2):445-451. PubMed ID: 31028607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
    Wilson LE; Pollack CE; Greiner MA; Dinan MA
    Breast Cancer Res Treat; 2018 Jul; 170(2):361-371. PubMed ID: 29536319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.
    Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes K; Wheeler SB
    Int J Technol Assess Health Care; 2016 Jan; 32(5):355-361. PubMed ID: 27958190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
    Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
    JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
    Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
    Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
    Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
    Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a Novel Network-Based Linchpin Score to Characterize Accessibility to the Oncology Physician Workforce in the United States.
    Moen EL; Brooks GA; O'Malley AJ; Schaefer A; Carlos HA; Onega T
    JAMA Netw Open; 2022 Dec; 5(12):e2245995. PubMed ID: 36525275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
    Schwedhelm TM; Rees JR; Onega T; Zipkin RJ; Schaefer A; Celaya MO; Moen EL
    BMC Cancer; 2020 Sep; 20(1):847. PubMed ID: 32883270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study.
    Nam G; Singh K; Lopresti ML; Ouseph MM; Wang LJ; Wang Y
    Technol Cancer Res Treat; 2021; 20():15330338211035037. PubMed ID: 34696631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
    Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
    JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
    Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
    J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
    Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
    Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence Disparities and Utilization Trends of Oncotype Dx Assay: A National Cancer Database Study.
    Chen S; Thacker C; Wang S; Young KA; Hoffman RL; Blansfield JA
    J Surg Res; 2023 Jun; 286():65-73. PubMed ID: 36758322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
    Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
    Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new methodology to predict the oncotype scores based on clinico-pathological data with similar tumor profiles.
    Al Masry Z; Pic R; Dombry C; Devalland C
    Breast Cancer Res Treat; 2024 Feb; 203(3):587-598. PubMed ID: 37926760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX
    Turner BM; Gimenez-Sanders MA; Soukiazian A; Breaux AC; Skinner K; Shayne M; Soukiazian N; Ling M; Hicks DG
    Cancer Med; 2019 Aug; 8(9):4176-4188. PubMed ID: 31199586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgeon peer network characteristics and adoption of new imaging techniques in breast cancer: A study of perioperative MRI.
    Tannenbaum SS; Soulos PR; Herrin J; Pollack CE; Xu X; Christakis NA; Forman HP; Yu JB; Killelea BK; Wang SY; Gross CP
    Cancer Med; 2018 Dec; 7(12):5901-5909. PubMed ID: 30444005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physician's peer exposure and the adoption of a new cancer treatment modality.
    Pollack CE; Soulos PR; Gross CP
    Cancer; 2015 Aug; 121(16):2799-807. PubMed ID: 25903304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.